Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarials
Toxicological Sciences · 2024
DOI: 10.1093/toxsci/kfae087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, 2024. Verfasst von Annie Delaunois und 9 weiteren Autor:innen. Beteiligte Einrichtung: UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium. Hauptthemen laut MEDLINE: Antimalarials, Myocytes, Cardiac, Induced Pluripotent Stem Cells, Aspartic Acid Endopeptidases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Quinoline-related antimalarial drugs have been associated with cardiotoxicity risk, in particular QT prolongation and QRS complex widening. In collaboration with Medicines for Malaria Venture, we discovered novel plasmepsin X (PMX) inhibitors for malaria treatment. The first lead compounds tested in anesthetized guinea pigs (GPs) induced profound QRS widening, although exhibiting weak inhibition of NaV1.5-mediated currents in standard patch clamp assays. To understand the mechanism(s) underlying QRS widening to identify further compounds devoid of such liability, we established a set of in vitro models including CaV1.2, NaV1.5 rate-dependence, and NaV1.8 patch clamp assays, human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM), and Langendorff-perfused isolated GP hearts. Six compounds were tested in all models including anesthetized GP, and 8 additional compounds were tested in vitro only. All compounds tested in anesthetized GP and isolated hearts showed a similar cardiovascular profile, consisting of QRS widening, bradycardia, negative inotropy, hypotension, and for some, QT prolongation. However, a left shift of the concentration–response curves was noted from in vitro to in vivo GP data. When comparing in vitro models, there was a good consistency between decrease in sodium spike amplitude in hiPSC-CM and QRS widening in isolated hearts. Patch clamp assay results showed that the QRS widening observed with PMX inhibitors is likely multifactorial, primarily due to NaV1.8 and NaV1.5 rate-dependent sodium blockade and/or calcium channel-mediated mechanisms. In conclusion, early de-risking of QRS widening using a set of different in vitro assays allowed to identify novel PMX inhibitors with improved cardiac safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium.
- B'SYS GmbH, 4108 Witterswil, Switzerland.
- MMV Medicines for Malaria Venture, ICC, 1215 Geneva, Switzerland.
- UCB Pharma, SL1 3WE Slough, United Kingdom.
ORCID-Profile: Annie Delaunois, Helga H J Gerets, Jean-Pierre Valentin
Zitieren
APA
Delaunois, A., Cardenas, A., de Haro, T., Gerets, H. H. J., Gryshkova, V., Hebeisen, S., Korlowski, C., Laleu, B., Lowe, M. A., & Valentin, J. P. (2024). Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarials. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfae087
Vancouver
Delaunois A, Cardenas A, de Haro T, Gerets HHJ, Gryshkova V, Hebeisen S, et al. Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarials. Toxicological Sciences. 2024. doi:10.1093/toxsci/kfae087
BibTeX
@article{Delaunois2024,
author = {Delaunois, Annie and Cardenas, Alvaro and de Haro, Teresa and Gerets, Helga H J and Gryshkova, Vitalina and Hebeisen, Simon and Korlowski, Chloé and Laleu, Benoit and Lowe, Martin A and Valentin, Jean-Pierre},
title = {Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarials},
journal = {Toxicological Sciences},
year = {2024},
doi = {10.1093/toxsci/kfae087}
}
EUVIMED